Johnson & Johnson risk profile
39 Normal where most of the sector sits
Measured 21 October 2026 from JNJ's filed statements. Recomputed nightly.
39 (Normal), driven by Competitive position at 54, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 19 | Contained | Stable | One-year price volatility — 20.7% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 30 | Normal | Worsening | Cash conversion — 0.92x |
| Leverage and coverage | 19 | Contained | Stable | Current ratio — 1.03x |
| Competitive position | 54 | Elevated | Stable | R&D-intensity gap against peers — -20.0 percentage points |
| Concentration | 51 | Elevated | Stable | Geographic concentration — 3,257 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51Abbott Laboratories 40
Financials, valuation and price history for Johnson & Johnson